Ceritinib dihydrochloride (Standard)

Ceritinib dihydrochloride (Standard) is the analytical standard of Ceritinib dihydrochloride. This product is intended for research and analytical applications. Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib dihydrochloride (LDK378 dihydrochloride) also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib dihydrochloride (LDK378 dihydrochloride) shows great antitumor potency[1][2].

Product Specifications

CAS Number

[1380575-43-8]

UNSPSC

12352100

Target

Anaplastic lymphoma kinase (ALK) ; IGF-1R; Insulin Receptor; Reference Standards

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer; Endocrinology

Smiles

CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(C(C)C)=O)=N3.[H]Cl.[H]Cl

Molecular Formula

C28H38Cl3N5O3S

Molecular Weight

631.06

References & Citations

[1]Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2- (2-isopropoxy-5-methyl-4- (piperidin-4-yl) phenyl) -N4- (2- (isopropylsulfonyl) phenyl) pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013, Jun 6.|[2]Rothschild SI. Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small celllung cancer. Transl Lung Cancer Res. 2014 Dec;3 (6) :379-81.